... Therapeutics, Inc., Portola Pharmaceuticals, and Xenon Pharmaceuticals. Merck also is partnering with academic institutions such as Oxford University ... Washington; and Montreal Heart Institute. In addition Merck is a founding member of the HRP Initiative, a joint ... standards of ethics and scientific integrity to everything we do.” Merck also is fighting cardiovascular disease by helping uninsured ...

... the brokerage firms are plainly entitled to assess this charge, because the way the transaction was structured, Old Merck stockholders do not keep their original shares. They got shiny new shares, with a new CUSIP ... and here, but J&J is now in final, binding arbitration with Merck over these issues. So, while the $20 exchange fee may not seem like much to the executives at Whitehouse Station, it ...

... term "Medical Informatics" into the controlled vocabulary pool used for various purposes at Merck. After a mere seven years, it looks like someone there has realized the need for Medical Informatics expertise. Unfortunately, ... genomic analyses/information with patient medical records -- to help position Merck in the rapidly evolving space of personalized medicine. --solid ...

... week. Shareholders of both the companies have already approved the deal in August. Merck expects to close the proposed merger by year end. ... in chemotherapy patients to Opko Health Inc. In addition, Merck agreed to sell its interest in Merial Ltd, an animal health ... Pfizer (PFE), which acquired Wyeth for $68 billion. Merck is faced with significant patent challenges over the next four years while ...

... is bringing its own leading animal-health business to the Merck deal, and combining the two would create a juggernaut, with more than a quarter of ... .6 billion in annual sales. And the odds have been Merck and Sanofi would eventually seek to reconstitute the alliance. ... price and the terms of how they would jointly run the business. But Merck and Sanofi worked out many of those issues when Sanofi paid ...

... withdraw the blockbuster painkiller for safety reasons. Since then, Merck (MRK, Fortune 500) has shrunk in size ... clinical development. Not all good science is created at Merck, we know that. Perhaps 1% of it is at our company. We’re much more externally focused ... true sea change? I’ve seen more change in Merck’s laboratories in the last five years than in the previous three decades ...